BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu Y, Xu J, Hu W, Wang F, Zhou Y, Gong W, Xu W. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases. Aging (Albany NY) 2021;13:14999-5012. [PMID: 34081623 DOI: 10.18632/aging.203061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Islam MT, Chen F, Chen H, Wahid A. Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel’s activity by suppressing the NF-kB signaling pathway. Front Oncol 2022;12:923270. [DOI: 10.3389/fonc.2022.923270] [Reference Citation Analysis]
2 Aryapour E, Kietzmann T. Mitochondria, mitophagy, and the role of deubiquitinases as novel therapeutic targets in liver pathology. J Cell Biochem 2022;123:1634-46. [PMID: 35924961 DOI: 10.1002/jcb.30312] [Reference Citation Analysis]
3 Tian Y, Liu K, Liu R, Qiu Z, Xu Y, Wei W, Xu X, Wang J, Ding H, Li Z, Bian J. Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. J Med Chem 2022. [PMID: 35786929 DOI: 10.1021/acs.jmedchem.2c00013] [Reference Citation Analysis]
4 Zhao J, Guo J, Wang Y, Ma Q, Shi Y, Cheng F, Lu Q, Fu W, Ouyang G, Zhang J, Xu Q, Hu X. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Front Oncol 2022;12:920287. [DOI: 10.3389/fonc.2022.920287] [Reference Citation Analysis]
5 Deng Y, Yu C, Chen L, Zhang X, Lei Q, Liu Q, Cai G, Liu F. ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. Front Pharmacol 2022;13:858901. [DOI: 10.3389/fphar.2022.858901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]